Yahoo! Finance Search - Finance Home - Yahoo! - Help

Monday, March 30 2015 4:04pm ET - U.S. Markets Closed.
Industry Center - Drug Manufacturers - Other
Industry Center > Drug Manufacturers - Other > News
More On This Industry
· Summary
·Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Biotechnology
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Major
· Drug Related Products
· Drugs - Generic
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
Drug Manufacturers - Other News
Latest News
Monday, Mar 30, 2015
·Teva Set for More Buys After Auspex
at - 1 hour, 9 minutes ago
·Are Auspex Shareholders Getting Enough in the Buyout?
- 2 hours, 14 minutes ago
·Teva Buys Tourette Syndrome Drug Firm Auspex for $3.2 Billion
at - 2 hours, 39 minutes ago
·Teva buying Auspex for $3.2 billion
AP - 2 hours, 56 minutes ago
·Can Boston Scientific Keep Its Turnaround Gains Going?
- Mon 12:25 pm ET
·Teva Pharmaceutical Swallows Auspex to Strengthen Its Drug Pipeline
at - Mon 11:44 am ET
·AUSPEX PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
PR Newswire - Mon 10:50 am ET
·Biotech Merger Monday Doesn't Squash Biotech Bubble Debate
at - Mon 10:43 am ET
·Nutrastar International, Inc. Announces Full Year 2014 Results
PR Newswire - Mon 9:00 am ET
·Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer
PR Newswire - Mon 8:45 am ET
·DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study
PR Newswire - Mon 8:30 am ET
·Teva to Acquire Auspex in $3.2 Billion Deal
at The Wall Street Journal Online - Mon 7:44 am ET
·Teva Buying Auspex Pharma for $3.5 Billion in Bid to Restart Growth
at - Mon 7:41 am ET
·Teva to buy Auspex in a $3.2 billion deal
at MarketWatch - Mon 7:12 am ET
·Leerink: Europe Deal Coming For Orexigen Therapeutics
- Mon 7:09 am ET
·Teva to buy Auspex for $101/share in cash
at CNBC - Mon 7:09 am ET
·Teva Reinforces Leadership Position in CNS with Acquisition of Auspex
Business Wire - Mon 7:00 am ET
Friday, Mar 27, 2015
·OREXIGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Orexigen Therapeutics, Inc. -- OREX
GlobeNewswire - Fri Mar 27
·Barrack, Rodos & Bacine Has Filed an Investor Class Action Against Orexigen Therapeutics, Inc.
GlobeNewswire - Fri Mar 27
·SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Orexigen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline -- OREX
GlobeNewswire - Fri Mar 27
More Latest News...
Sponsor Results
Best Pharma Direct Mktg
The Internet Is The New Direct Mktg Targeted Marketing Every time.Call.
Tailored solutions in molecular biology and bioinformatics
College Degree Online
Get Degree With $5,730 University or College Grant if Qualify. Act Now.
(What's This?)

RSS Feeds

Add headlines to your
personalized My Yahoo Page
( About My Yahoo and RSS )

Drug Manufacturers - Other Headlines
More Finance RSS Feeds

Copyright © 2015 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2015 Morningstar, Inc. All Rights Reserved. Company information © 2015 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2015, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?